<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271387</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VEC-162-1105</org_study_id>
    <nct_id>NCT01271387</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment</brief_title>
  <official_title>An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon With That in Matched Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to understand whether there is any difference in the&#xD;
      amount of tasimelteon (including its breakdown products) in the blood in individuals with&#xD;
      mild or moderate liver disease compared to individuals who have normal liver function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will employ an open-label, parallel-group design. Up to 32 subjects will be&#xD;
      enrolled in 3 groups: Group 1 will consist of 8 subjects with mild hepatic impairment; Group&#xD;
      2 will consist of 8 subjects with moderate hepatic impairment; Group 3 will consist of up to&#xD;
      16 healthy subjects matched by gender, age, smoking status, and body mass index, to Groups 1&#xD;
      and/or 2. For each group, there will be a 21-day screening period, a baseline period, a&#xD;
      single-dose treatment period with an on-site observation period of 36 hours, and a study&#xD;
      completion evaluation conducted after the last PK blood sample is drawn. Each subject will&#xD;
      receive a single 20-mg dose of tasimelteon, after which safety assessments will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations and PK of tasimelteon</measure>
    <time_frame>36 hours</time_frame>
    <description>To assess plasma concentrations and pharmacokinetics of tasimelteon in subjects with mild or moderate hepatic impairment compared to healthy subjects with normal hepatic function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations and PK of tasimelteon metabolites</measure>
    <time_frame>36 hours</time_frame>
    <description>To assess plasma concentrations and pharmacokinetics of tasimelteon metabolites in subjects with mild or moderate hepatic impairment compared to healthy subjects with normal hepatic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>36 hours</time_frame>
    <description>To assess the safety and tolerability of a single 20-mg oral dose of tasimelteon.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tasimelteon</intervention_name>
    <description>20 mg tasimelteon capsules, PO single dose</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <other_name>VEC-162</other_name>
    <other_name>BMS-214778</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          -  Ability and acceptance to provide written informed consent;&#xD;
&#xD;
          -  Men or women between 18 - 75 years, inclusive;&#xD;
&#xD;
          -  Subjects with Body Mass Index (BMI) of &gt;18 and &lt;35 kg/m2;&#xD;
&#xD;
          -  Women of child-bearing potential must be using an acceptable method of birth control;&#xD;
&#xD;
          -  Willing and able to comply with study requirements and restrictions;&#xD;
&#xD;
        Subjects with mild or moderate hepatic impairment:&#xD;
&#xD;
          -  Stable hepatic impairment satisfying the criteria for Class A or B of the modified&#xD;
             Child-Pugh classification documented by medical history;&#xD;
&#xD;
          -  Subjects with Moderate hepatic impairment must also have either liver cirrhosis or&#xD;
             physical signs consistent with a clinical diagnosis of liver cirrhosis&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Healthy matched controls:&#xD;
&#xD;
          -  Matched to subjects with hepatic impairment by gender, age, BMI, and smoking status&#xD;
&#xD;
          -  Good health as determined by past medical history, physical examination,&#xD;
             electrocardiogram, laboratory tests, vital signs and urinalysis;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers unable or unwilling to limit consumption;&#xD;
&#xD;
          -  Exposure to any investigational drug, including placebo, within 30 days of dosing;&#xD;
&#xD;
          -  Blood Donation or loss of 400 mL or more within two months prior to dosing;&#xD;
&#xD;
          -  Significant illness within the two weeks prior to dosing;&#xD;
&#xD;
          -  History of autonomic dysfunction;&#xD;
&#xD;
          -  History of acute or chronic bronchospastic disease, including asthma and chronic&#xD;
             obstructive pulmonary disease, treated or not treated;&#xD;
&#xD;
          -  A known hypersensitivity to tasimelteon or drugs similar to tasimelteon including&#xD;
             melatonin;&#xD;
&#xD;
          -  Pregnant or lactating females;&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 12 months prior to screening&#xD;
&#xD;
          -  History of immunocompromise, including a positive HIV (ELISA and Western blot) test&#xD;
             result;&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution or excretion of any drug;&#xD;
&#xD;
          -  Clinically significant ECG abnormalities or vital sign abnormalities at screening or a&#xD;
             history of unstable, severe, or clinically significant cardiovascular disease;&#xD;
&#xD;
        Subjects with mild or moderate hepatic impairment:&#xD;
&#xD;
          -  Clinically significant abnormal findings, not consistent with clinical disease, upon&#xD;
             physical examination, ECG, or laboratory evaluation;&#xD;
&#xD;
          -  Current symptoms or past history (within the last 6 months) of encephalopathy;&#xD;
&#xD;
          -  Severe ascites;&#xD;
&#xD;
          -  Previous surgical porto-systemic shunt including transjugular intrahepatic&#xD;
             portosystemic shunt (TIPS);&#xD;
&#xD;
          -  Progressive liver disease within 4 weeks prior to screening.&#xD;
&#xD;
        Healthy matched controls:&#xD;
&#xD;
          -  Use of any prescription medication within 1 month of dosing, and OTC medication within&#xD;
             14 days prior to dosing;&#xD;
&#xD;
          -  History or presence of liver disease or liver injury;&#xD;
&#xD;
          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanda Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Vanda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver disease</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

